Remove Cannabis Remove Clinical Trials Remove Microdosing Remove Treatment
article thumbnail

New Zealand Government Grants $650K For LSD Microdosing Trials

Cannabis Law Report

Mindbio Therapeutics , a subsidiary of cannabis and psychedelics holding company Blackhawk Growth Corp. million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). Press Release.

article thumbnail

Mind Medicine, Inc – trial to test LSD microdosing as an ADHD treatment

Cannabis Law Report

a Canadian biotech firm, is entering Phase II clinical trials for two experimental treatments. According to its website, one trial involves an ibogaine-derived drug for treating opioid addiction. The other trial will test LSD microdosing as an ADHD treatment. Mind Medicine, Inc. ,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What You Need to Know About Microdosing

The Joint Blog

While over the last few years, microdosing has become extremely popular, the act of microdosing has been recommended by experts for at least two decades. There are also many different substances that you can microdose, from psilocybin mushrooms to delta-8. In this article, we are going to cover microdose of legal substances.

article thumbnail

Indiana Nurse Could Face A Decade In Prison For Microdosing Psilocybin Mushrooms

Cannabis Law Report

For Jessica Thornton, who has lived with treatment-resistant depression since her senior year at high school, psychedelics represent a lifeline. Desperate to find any solution, she tried microdosing psilocybin mushrooms after researching the practice online. I felt as if I was in a constant battle with myself. “I

article thumbnail

Press Release: Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

Cannabis Law Report

Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. It’s clear that alternative treatment options are necessary to combat depression and other mental illnesses, which is where companies developing psychedelic-based treatments like Optimi Health Corp.

article thumbnail

Press Release: Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

Cannabis Law Report

Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”. VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (

Therapy 52
article thumbnail

Article: Intellectual Property Due Diligence in Psychedelics

Cannabis Law Report

The market for psychedelic substances is projected to grow rapidly, potentially outpacing the legal US cannabis market. For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art.